RT Journal Article
SR Electronic
T1 Preliminary Results of Seroprevalence of SARS-CoV-2 at Community Clinics in Tokyo
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.29.20085449
DO 10.1101/2020.04.29.20085449
A1 Takita, Morihito
A1 Matsumura, Tomoko
A1 Yamamoto, Kana
A1 Yamashita, Erika
A1 Hosoda, Kazutaka
A1 Hamaki, Tamae
A1 Kusumi, Eiji
YR 2020
UL http://medrxiv.org/content/early/2020/05/05/2020.04.29.20085449.abstract
AB Serological evaluation with SARS-CoV-2 specific IgG antibody will be an alternative way to know the pandemic of novel coronavirus disease (COVID-19) if the capacity for diagnostic PCR test is limited. The point-of-care test to detect SARS-CoV-2 specific IgG antibody in peripheral blood (n =202) was performed in two community clinics in Tokyo, Japan. The overall positive rate of SRAS-CoV-2 IgG antibody was 5.9% (95% confidence interval[CI]: 3.1-10.1). Higher rate was observed for healthcare workers (n =55, 9.1 [3.0-20.0]). The limitation on antibody tests includes low sensitivity and potent cross-reactivity with the previous coronavirus. Robust healthcare policy to efficiently monitor COVID-19 spread is warranted in Tokyo.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was performed by intramural funding of Navitas Clinic.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analyzed during the current study are not publicly available due to ongoing further analyses but are available from the corresponding author on reasonable request.